Skip to main content
BIO-GENE TECHNOLOGY LTD logo

BIO-GENE TECHNOLOGY LTD — Investor Relations & Filings

Ticker · BGT ISIN · AU000000BGT8 ASX Professional, scientific and technical activities
Open in API
Filings indexed 452 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country AU Australia
Listing ASX BGT

About BIO-GENE TECHNOLOGY LTD

https://bio-gene.com.au/

Bio-Gene Technology Ltd is a technology company focused on the development and commercialization of novel insecticides derived from naturally occurring chemistry. The company addresses the global challenge of insecticide resistance through its proprietary platform based on beta-triketone chemistry. Its primary product candidates include Flavocide, a nature-identical version of a compound found in specific eucalyptus species, and Qcide, a natural oil extract. These solutions are designed for diverse applications, including crop protection, grain storage, public health, and animal health. By utilizing a unique mode of action, the company provides alternatives to traditional chemical pesticides, aiming to deliver effective pest management with a favorable safety profile for non-target organisms and the environment.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 643.4KB
Regulatory Filings Classification · 85% confidence The document is an ASX market announcement requesting a trading halt under Listing Rule 17.1 pending a proposed capital raising. It is a regulatory compliance notice rather than substantive report content on financial results or a formal financing update. It fits the fallback category for general regulatory announcements and compliance filings.
2026-05-21 English
BGT to expand Flavocide and Qcide evaluation to Asia 3 pages 603.4KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement detailing Bio-Gene’s expansion of product evaluation (vector control testing) in Asia. It contains no financial results, no meeting materials, no fundraising, no legal or governance specifics—it is a corporate update filed for regulatory compliance. It does not include substantive financial statements or executive changes. Therefore it falls under the general “Regulatory Filings” category as a miscellaneous announcement.
2026-05-20 English
Key insecticide combinations patent allowed in the US 2 pages 590.5KB
Regulatory Filings
2026-05-05 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 778.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an 'ASX Announcement' titled 'Quarterly Activities Report and Appendix 4C'. It provides a comprehensive update on company activities, regulatory progress, and includes the mandatory Appendix 4C cash flow statement for the quarter ended 31 March 2026. As it contains substantive financial data (cash flow statement) and operational analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q3 2026
2026-04-26 English
Investor Presentation 21 pages 2.8MB
Investor Presentation Classification · 85% confidence The document is an ASX announcement titled “Bio-Gene to attend investor meetings…,” and explicitly states that an “investor presentation is attached below.” The bulk of the text consists of slide headings, investment highlights, pipeline data, charts, and disclaimers typical of a pitch deck. It is not a regulatory filing, earnings release, or annual/interim report, but a presentation for investors. Therefore, it is classified as an Investor Presentation.
2026-04-19 English
Change of Auditor 2 pages 541.5KB
Regulatory Filings
2026-04-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.